<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02688842</url>
  </required_header>
  <id_info>
    <org_study_id>Firehawk_LS</org_study_id>
    <nct_id>NCT02688842</nct_id>
  </id_info>
  <brief_title>Evaluation of New Specifications (38mm) of FirehawkTM in the Treatment of Coronary Heart Disease</brief_title>
  <acronym>Firehawk_38</acronym>
  <official_title>The Safety and Effectiveness Evaluation of New Specifications (38mm) of FirehawkTM Sirolimus Target-eluting Coronary Stent System in the Treatment of Coronary Heart Disease: a Prospective, Multicenter, Single-group Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai MicroPort Medical (Group) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai MicroPort Medical (Group) Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evalute the clinical safety and effectiveness of released
      specification (38mm) of FirehawkTM Sirolimus target-eluting coronary stent system.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 2014</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>all patients implanted Firehawk stent of new specification (38mm long)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-stent late lumen loss</measure>
    <time_frame>9 month after stent implantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target lesion failure</measure>
    <time_frame>30 days, 6 months, 12 months and 2-5 years after stent implantation</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation of the released specification (38mm) of FirehawkTM rapamycin target-eluting coronary stent systems</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Rapamycin target-eluting coronary stent systems (38mm)</intervention_name>
    <arm_group_label>treatment group</arm_group_label>
    <other_name>Firehawk-38</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18-80 years of age, males or non-pregnant women;

          2. Evidence of silent ischemia, stability or in patients with old myocardial infarction
             or unstable angina;

          3. Primary target lesion, in situ coronary artery disease;

          4. Target lesion length ≤ 60mm, target lesion diameter 2.75mm or 4.0mm (Visual method);

          5. The target lesion diameter stenosis ≥ 70% (Visual method);

          6. Each target lesion implantation the same stent (Firehawk stand);

          7. With indications for coronary artery bypass surgery;

          8. To understand the purpose of testing, voluntary and informed consent, patients
             undergoing invasive imaging follow-up.

        Exclusion Criteria:

          1. Within 1 month of any acute myocardial infarction;

          2. Chronic total occlusion (TIMI grade 0 flow before surgery), left main coronary artery
             disease, mouth lesions, multiple-vessel lesions, branch diameter ≥ 2.5mm bifurcation
             lesions and vascular lesions of the bridge;

          3. Severe calcified lesions that cannot be successfully expanded and distorting lesions
             not suitable for stent delivery;

          4. In-stent Restenosis lesions;

          5. Intracoronary implantation of any branding stents within 1 year;

          6. Severe congestive heart failure (NYHA class III and above) ,left ventricular ejection
             fraction or &lt;40% (ultrasound or left ventricular angiography);

          7. Preoperative renal function serum creatinine &gt;2.0mg/DL;

          8. Bleeding, active gastrointestinal ulcers, brain hemorrhage or subarachnoid hemorrhage
             and half year history of ischemic stroke, antiplatelet agents and would not allow an
             anticoagulant therapy contraindications patients undergoing antithrombotic therapy;

          9. Aspirin, clopidogrel, heparin, contrast agent, poly lactic acid polymer and rapamycin
             allergies;

         10. The patient's life expectancy is less than 12 months;

         11. Top participated in other drug or medical device and does not meet the primary study
             endpoint in clinical trials time frame;

         12. Researchers determine patient compliance is poor, unable to complete the study in
             accordance with the requirements;

         13. Heart transplantation patients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Runlin Gao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fu Wai Hospital &amp; National Center for Cardiovascular Diseases in China</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fu Wai Hospital</name>
      <address>
        <city>Peking</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2016</study_first_submitted>
  <study_first_submitted_qc>February 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2016</study_first_posted>
  <last_update_submitted>July 31, 2017</last_update_submitted>
  <last_update_submitted_qc>July 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

